Literature DB >> 22024360

Α-synuclein misfolding and Parkinson's disease.

Leonid Breydo1, Jessica W Wu, Vladimir N Uversky.   

Abstract

Substantial evidence links α-synuclein, a small highly conserved presynaptic protein with unknown function, to both familial and sporadic Parkinson's disease (PD). α-Synuclein has been identified as the major component of Lewy bodies and Lewy neurites, the characteristic proteinaceous deposits that are the hallmarks of PD. α-Synuclein is a typical intrinsically disordered protein, but can adopt a number of different conformational states depending on conditions and cofactors. These include the helical membrane-bound form, a partially-folded state that is a key intermediate in aggregation and fibrillation, various oligomeric species, and fibrillar and amorphous aggregates. The molecular basis of PD appears to be tightly coupled to the aggregation of α-synuclein and the factors that affect its conformation. This review examines the different aggregation states of α-synuclein, the molecular mechanism of its aggregation, and the influence of environmental and genetic factors on this process.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22024360     DOI: 10.1016/j.bbadis.2011.10.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  188 in total

1.  Transient β-hairpin formation in α-synuclein monomer revealed by coarse-grained molecular dynamics simulation.

Authors:  Hang Yu; Wei Han; Wen Ma; Klaus Schulten
Journal:  J Chem Phys       Date:  2015-12-28       Impact factor: 3.488

Review 2.  GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.

Authors:  Parker H Johnson; Neal J Weinreb; James C Cloyd; Paul J Tuite; Reena V Kartha
Journal:  Mol Genet Metab       Date:  2019-10-23       Impact factor: 4.797

Review 3.  Using NMR spectroscopy to investigate the role played by copper in prion diseases.

Authors:  Rawiah A Alsiary; Mawadda Alghrably; Abdelhamid Saoudi; Suliman Al-Ghamdi; Lukasz Jaremko; Mariusz Jaremko; Abdul-Hamid Emwas
Journal:  Neurol Sci       Date:  2020-04-24       Impact factor: 3.307

4.  Definition of a molecular pathway mediating α-synuclein neurotoxicity.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

5.  A pH-dependent switch promotes β-synuclein fibril formation via glutamate residues.

Authors:  Gina M Moriarty; Michael P Olson; Tamr B Atieh; Maria K Janowska; Sagar D Khare; Jean Baum
Journal:  J Biol Chem       Date:  2017-07-14       Impact factor: 5.157

6.  Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.

Authors:  Wing-Hin Lee; Ching-Yee Loo; Mary Bebawy; Frederick Luk; Rebecca S Mason; Ramin Rohanizadeh
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

Review 7.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

8.  Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways.

Authors:  Annadurai Anandhan; Humberto Rodriguez-Rocha; Iryna Bohovych; Amy M Griggs; Laura Zavala-Flores; Elsa M Reyes-Reyes; Javier Seravalli; Lia A Stanciu; Jaekwon Lee; Jean-Christophe Rochet; Oleh Khalimonchuk; Rodrigo Franco
Journal:  Neurobiol Dis       Date:  2014-12-08       Impact factor: 5.996

9.  Potassium depolarization and raised calcium induces α-synuclein aggregates.

Authors:  Jordan Follett; Bonnie Darlow; Mathew B Wong; Jacob Goodwin; Dean L Pountney
Journal:  Neurotox Res       Date:  2012-12-19       Impact factor: 3.911

Review 10.  Exploring the accessible conformations of N-terminal acetylated α-synuclein.

Authors:  Gina M Moriarty; Maria K Janowska; Lijuan Kang; Jean Baum
Journal:  FEBS Lett       Date:  2013-03-13       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.